An interventional study of Using m-health for monitoring and education provision and Standard care in Quality of Life, Self Efficacy and Chronic Kidney Diseases, sponsored by Universitas Muhammadiyah Yogyakarta. Not yet recruiting at 1 site in Indonesia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-12.
Sponsored by Universitas Muhammadiyah Yogyakarta · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Renal Insufficiency, Chronic with a site in Indonesia — 6 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Indonesia.
Among the 23 studies in Renal Insufficiency, Chronic with a site in Indonesia, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2024, is one of 9 with no phase, and was the 12th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →6 of the 23 studies in Renal Insufficiency, Chronic with a site in Indonesia are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Indonesia, United States, Argentina and 34 more countries
Ages 18+
Evi Liliek Wulandari · Sites in Indonesia
Ages 18+
Indiana University · Sites in Indonesia, United States, Argentina and 30 more countries
Ages 0 min–2 wk
Universitas Indonesia · Sites in Indonesia
Ages 18–59
Universitas Indonesia · Sites in Indonesia
Ages 18–59
A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3 · Phase 4 2
First in 2009; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 45 across the 16 interventional studies, 200 across the 7 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 23 have an industry lead sponsor. The 10 most frequent:
Universitas Muhammadiyah Yogyakarta is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Universitas Muhammadiyah Yogyakarta has 2 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
3 of the studies in Renal Insufficiency, Chronic with a site in Indonesia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07888777Universitas IndonesiaManual Acupuncture for Intradialytic Nausea and Vomiting in Patients Undergoing Hemodialysis | 2026-11 |
| NCT07887386Universitas IndonesiaManual Acupuncture for Intradialytic Fatigue in CKD Patients | 2026-12 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Renal Insufficiency, Chronic with a site in Indonesia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
One of the goals in the Sustainable Development Goals (SDGs) is the availability of a healthy and prosperous life for all ages. This goal mentions health priorities i.e. non-communicable diseases. Chronic kidney failure (CRF) is one of the non-communicable diseases that is the main cause of death and disability both in the world and in Indonesia. The prevalence of CRF in Indonesia is 0.5% with 83.2% of patients being of productive age and the highest number of CRF patients in North Kalimantan, Southeast Sulawesi, DKI Jakarta and Yogyakarta. Monitoring and evaluation of patients with CRF is currently mostly carried out conventionally not using health technology that is integrated with hospital information systems. This study aims to design and provide a health information system for patients with CRF, hereinafter referred to as SIKIDI, which integrates mobile-health applications used independently by patients with existing information systems in hospitals.
One of the goals in the Sustainable Development Goals (SDGs) is the availability of a healthy and prosperous life for all ages. This goal mentions health priorities i.e. non-communicable diseases. Chronic kidney failure (CRF) is one of the non-communicable diseases that is the main cause of death and disability both in the world and in Indonesia. The prevalence of CRF in Indonesia is 0.5% with 83.2% of patients being of productive age and the highest number of CRF patients in North Kalimantan, Southeast Sulawesi, DKI Jakarta and Yogyakarta. Monitoring and evaluation of patients with CRF is currently mostly carried out conventionally not using health technology that is integrated with hospital information systems. This study aims to design and provide a health information system for patients with CRF, hereinafter referred to as SIKIDI, which integrates mobile-health applications used independently by patients with existing information systems in hospitals.
This research is a multicenter basic research in four provinces. In the first year, the level of readiness and patient needs in using the mobile-health application will be seen. Furthermore, SIKIDI will be developed for monitoring the condition of patients integrated with existing systems in hospitals, and will be tested on patients with CRF at partner hospitals in DIY provinces. In addition, the ease and comfort of patients when using SIKIDI will also be seen. The output of the first year is publication in accredited national journals and prototypes of SIKIDI version 1.
In the second phase, SIKIDI version 2 will be developed which is equipped with educational features that are expected to increase patient knowledge in self-management. The trial process will be carried out at partner hospitals to see the effectiveness of educational features with patient self-management capabilities. The advantages of SIKIDI are: (1) integrated with hospital information systems; (2) include patients and families in condition monitoring; (3) improve the self-efficacy ability of patients and families. The output of year 2 is publication in reputable international journals and prototypes of SIKIDI version 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The experimental arm will be given to access to m-health to monitor and education provision.
Behavioral: Using m-health for monitoring and education provision
The comparator group will be given standard care
Other: Standard care
The intervention group will be given access to m-health. The m-health aims to monitor patient's status i.e blood pressure, heart rate, fluid intake, dietary intake. In addition, there will be education provided through the m-health. The education will be on fluid and diet adherence
The comparator group will be given standard and routine care
Quality of Life that will be measured using KDQOL before and after intervention
The quality of life will be measured using Kidney Disease Quality of Life, (KDQOL) before and after the intervention. The max score is 100 and minimum score is 50
Time frame: four weeks
Self-efficacy that will be measured using CKD SE before and after
The self-efficacy will be measured using validated tool CKD Self-Efficaccy (CKD SE). The maximum score is 100, and the minimum score is 0
Time frame: four weeks
Plan to share: Undecided — The data will be provided upon request
No publications or documents are linked to this record.
Start is estimated for Mar 2024; primary completion for Oct 2024, 7 months later.
Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 7 months is below that.
Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Universitas Muhammadiyah Yogyakarta